Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Key AstraZeneca lung cancer treatment misses study goal

November 16, 2018 10:35 AM
125 0

(Reuters) - AstraZeneca (AZN.L) said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

The study, known as “Mystic”, was among the industry’s most anticipated clinical experiments and was viewed as central to proving the value of the group’s new drug pipeline and its future as an independent company, after it spurned a $118 billion takeover attempt by Pfizer (PFE.N) in 2014.

Read more

Share in social networks:

Comments - 0